IRIS
TOMELLERI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.422
AS - Asia 1.670
NA - Nord America 1.624
SA - Sud America 284
Continente sconosciuto - Info sul continente non disponibili 170
AF - Africa 31
OC - Oceania 3
Totale 6.204
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.522
RU - Federazione Russa 1.218
SG - Singapore 555
CN - Cina 533
IT - Italia 356
RO - Romania 265
BR - Brasile 237
HK - Hong Kong 205
SE - Svezia 170
VN - Vietnam 140
DE - Germania 118
FR - Francia 81
BD - Bangladesh 71
CA - Canada 65
GB - Regno Unito 63
FI - Finlandia 39
IN - India 32
JP - Giappone 25
PH - Filippine 25
AR - Argentina 22
PL - Polonia 22
MX - Messico 21
NL - Olanda 21
ES - Italia 20
AT - Austria 14
ID - Indonesia 11
TR - Turchia 11
ZA - Sudafrica 11
MY - Malesia 9
LT - Lituania 8
AE - Emirati Arabi Uniti 7
CO - Colombia 7
EG - Egitto 7
IQ - Iraq 7
UA - Ucraina 6
EC - Ecuador 5
IE - Irlanda 5
MK - Macedonia 5
NP - Nepal 5
UZ - Uzbekistan 5
VE - Venezuela 5
IR - Iran 4
JM - Giamaica 4
SA - Arabia Saudita 4
XK - ???statistics.table.value.countryCode.XK??? 4
AU - Australia 3
GT - Guatemala 3
KE - Kenya 3
KR - Corea 3
KZ - Kazakistan 3
MA - Marocco 3
PY - Paraguay 3
AL - Albania 2
BE - Belgio 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HR - Croazia 2
IL - Israele 2
PE - Perù 2
PK - Pakistan 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
GE - Georgia 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LV - Lettonia 1
MN - Mongolia 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SC - Seychelles 1
SN - Senegal 1
TG - Togo 1
TN - Tunisia 1
TW - Taiwan 1
VI - Stati Uniti Isole Vergini 1
Totale 6.038
Salva come PNG Salva come JPEG
Città #
Singapore 281
Moscow 241
Ashburn 227
Dallas 208
Hong Kong 198
San Jose 168
Shanghai 116
Milan 84
New York 80
Beijing 76
Council Bluffs 74
Hefei 63
Munich 59
Lauterbourg 55
Ho Chi Minh City 54
Los Angeles 54
Santa Clara 41
Boardman 38
São Paulo 36
Lawrence 31
Princeton 31
Rome 26
Hanoi 23
Orem 21
Helsinki 20
Nuremberg 19
Warsaw 19
Montreal 18
Tokyo 17
Atlanta 16
Denver 16
Chicago 15
Phoenix 14
Brooklyn 13
London 13
Turku 13
Cesano Boscone 12
Toronto 12
Boston 10
Chennai 10
Guangzhou 10
Johannesburg 10
Poplar 10
Stockholm 10
Makati City 9
Naples 9
Pune 9
Ankara 8
Manchester 8
Pietra Ligure 8
Rio de Janeiro 8
Seattle 8
Shenzhen 8
Mexico City 7
Verona 7
Bari 6
Brescia 6
City of London 6
Da Nang 6
Falkenstein 6
Frankfurt am Main 6
Haiphong 6
Lappeenranta 6
Amsterdam 5
Ancona 5
Buffalo 5
Dublin 5
Florence 5
Genoa 5
Houston 5
Querétaro 5
San Francisco 5
Tashkent 5
Trento 5
Vittoria 5
Wolfhagen 5
Barnet 4
Brasília 4
Cairo 4
Charlotte 4
Foshan 4
Goito 4
Jiaxing 4
Miami 4
Pisa 4
Pristina 4
Quezon City 4
Skopje 4
Sydney 4
Taizhou 4
The Dalles 4
Turin 4
Valencia 4
Vancouver 4
Vienna 4
Zhengzhou 4
Alessandria 3
Annapolis 3
Baie-D'Urfé 3
Bauru 3
Totale 2.856
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 395
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 184
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 179
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 178
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 154
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 145
A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM) 142
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 134
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 130
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease 126
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 121
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study 120
Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort 116
Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: A real-life experience from a monocentric cohort 115
Drug retention rates of biological agents in adult onset Still's disease 114
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 112
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 111
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 109
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 108
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 104
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 103
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 103
Giant cell arteritis: Update on clinical manifestations, diagnosis, and management 103
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 103
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 101
Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India 99
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 99
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 98
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 97
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients 95
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 95
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 95
VEXAS associated acute disseminated Encephalo-Myelitis (ADEM)-like syndrome: A case report and review of the literature 92
Clinically isolated aortitis successfully treated with methotrexate monotherapy 91
An enlightening scan 90
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies 90
LONG-TERM PATHOPHYSIOLOGIC AND PROGNOSTIC EVALUATION OF DIFFERENT DISEASE SUBSETS IN GIANT CELL ARTERITIS 84
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 80
The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort 79
Clinical and dermoscopic description of accelerated nodulosis after tocilizumab treatment for an isolated aortitis with coronary involvement 77
HETEROGENEITY OF CYTOPENIAS IN VEXAS SYNDROME: A SINGLE CENTRE EXPERIENCE 75
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 73
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 69
Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease 68
Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study 67
Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement 63
Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: A monocentric survey 62
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic 62
Response to: 'Correspondence on Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: A monocentric survey' by Comarmond et al 61
Efficacy of interleukin-1 blockade with anakinra in the management of post-COVID-19 steroid-dependent multisystem inflammatory syndrome: a case report 57
Failure of first anti-TNF agent in Takayasu’s arteritis: To switch or to swap? 56
Potential acceptance of COVID-19 vaccine in rheumatological patients: A monocentric comparative survey 56
Retention rates of different Janus kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort 55
Large Vessel Vasculitis Affecting the Aorta and Its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature 55
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series 54
Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis 52
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance 51
Multimodal chorioretinal imaging in erdheim-chester disease 50
One year later: The case of tocilizumab in COVID-19 49
Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients 49
Myocardial infarction in giant cell arteritis: It is all a matter of balance 48
Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease 47
The target on B cells in Systemic Sclerosis: a “midsummer dream” to extinguish inflammation and prevent early disease progression to fibrosis 46
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply 46
Spontaneous coronary-artery dissection 39
Safety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience 9
Real-life use of high-dose anakinra in patients with COVID-19 treated with remdesivir 8
Erythroid-stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort 3
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome 3
Totale 6.204
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.070
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.070
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202264 0 0 23 17 2 4 6 2 4 3 0 3
2022/2023305 75 58 15 3 8 36 29 38 19 10 9 5
2023/2024403 11 30 52 36 34 59 33 44 3 7 15 79
2024/20251.367 100 29 44 39 68 89 408 118 161 103 91 117
2025/20263.751 256 229 258 483 295 106 292 316 1.041 209 116 150
2026/2027278 139 139 0 0 0 0 0 0 0 0 0 0
Totale 6.204